Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis

Molecular Medicine

Volumn 13, Issue 1-2, 2007, Pages 40-58

  Edwards, Christopher J ^a,b   Feldman, Jeffrey L ^c   Beech, Jonathan ^a   Shields, Kathleen M ^c   Stover, Jennifer A ^e   Trepicchio, William L ^d   Larsen, Glenn ^f   Foxwell, Brian M J ^a   Brennan, Fionula M ^a   Feldmann, Marc ^a   Pittman, Debra D ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e Thermo Fisher Scientific   (United States)

^f Hydra Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHAPERONE; CYTOKINE; ENZYME; PROTEINASE; RNA;

ADULT; AGED; ARTICLE; CALCIUM BINDING; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR MEMBRANE; K NEAREST NEIGHBOR; MALE; MITOCHONDRIAL GENE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RIBOSOME; RNA ANALYSIS; RNA TRANSLATION; SIGNAL TRANSDUCTION; STRUCTURAL GENE; UNINDEXED SEQUENCE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 6; CLUSTER ANALYSIS; FEMALE; FLUORESCENCE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA; TRANSCRIPTION, GENETIC;

EID: 34249001625     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-000056.Edwards     Document Type: Article

References (61)

1. Markenson JA. (1991) Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin. Arthritis Rheum. 21(2 Suppl 1):4-12.
2. Wong JB, Ramey DR, Singh G. (2001) Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum. 44(12):2746-9.
3. No author. (2002) Guidelines for the management of rheumatoid arthritis: update. Arthritis Rheum. 46:328-46.
4. Feldmann M, Maini RN. (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9:1245-50.
5. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. (1995) Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J. Rheumatol. 22:1792-6.
6. Bathon JM et al. (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Me.d 343:1586-93.
7. Lipsky PE et al. (2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343:1594-602.
8. Quinn MA et al. (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52:27-35.
9. Combe B et al. (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 44:1736-43.
10. Dixey J, Solymossy C, Young A. (2004) Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J. Rheumatol. 69 (Suppl):48-54.
11. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 64:196-201.
12. van Zeben D, Breedveld FC. (1996) Prognostic factors in rheumatoid arthritis. J. Rheumatol. 44(Suppl):31-3.
13. Aune TM, Maas K, Parker J, Moore JH, Olsen NJ. (2004) Profiles of gene expression in human autoimmune disease. Cell Biochem. Biophys. 40:81-96.
14. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. (2004) Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin. Exp. Immunol. 138:164-70.
15. Qing X, Putterman C. (2004) Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun. Rev. 3:505-9.
16. Rus V et al. (2004) Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin. Immunol. 112:231-4.
17. van't Veer LJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-6.
18. Arnett FC et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-24.
19. Clancy BM et al. (2003) A gene expression profile for endochondral bone formation: oligonucleotide microarrays establish novel connections between known genes and BMP-2-induced bone formation in mouse quadriceps. Bone 33:46-63.
20. Hill AA, Brown EL, Whitley MZ, Tucker-Kellogg G, Hunter CP, Slonim DK. (2001) Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls. Genome. Biol. 2:RESEARCH0055.
21. Chiang DY, Brown PO, Eisen MB. (2001) Visualizing associations between genome sequences and gene expression data using genome-mean expression profiles. Bioinformatics 17(Suppl 1):S49-55.
22. Welch BL. (1951) On the comparison of several mean values: an alternative approach. Biometrika 38:330-6.
23. Benjamini Y, Hochberg Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal. Stat. Soc. B 57:289-300.
24. Bonferroni CE. (1935) II calcolo delle assicurazioni su gruppi di teste. Studi in onore del Professore Salvatore. Rome. p. 11-60.
25. Bonferroni CE. (1936) Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze 8:3-62.
26. Golub TR et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-7.
27. Jawaheer D et al. (2003) Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum. 48:906-16.
28. Foxwell BM, Bondeson J, Brennan F, Feldmann M. (2000) Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogeneity in the requirement for NFkappaB in tumor necrosis factor production. Ann. Rheum. Dis. 59 Suppl 1:i54-59.
29. Keyszer GM et al. (1995) Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J. Rheumatol. 22:275-81.
30. Ota T, Katsuki I. (1998) Ferritin subunits in sera and synovial fluids from patients with rheumatoid arthritis. J. Rheumatol. 25:2315-8.
31. Akin E, Aversa J, Steere AC. (2001) Expression of adhesion molecules in synovia of patients with treatment-resistant lyme arthritis. Infect. Immun. 69:1774-80.
32. Makarov SS. (2001) NF-kappaB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. 3:200-6.
33. Sumariwalla PF, Malfait AM, Feldmann M. (2004) P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumor necrosis factor. Clin. Exp. Immunol. 136:67-75.
34. Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M. (1992) Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur. J. Immunol. 22:1907-12.
35. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. (1995) TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand. J. Immunol. 42:158-65.
36. Cope AP et al. (1993) Differential regulation of tumor necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine 5:205-12.
37. Shealy DJ. et al. (2002) Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 4:R7.
38. Williams RO, Feldmann M, Maini RN. (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 89:9784-8.
39. Boiardi L, Macchioni P, Meliconi R, Pulsatelli L, Facchini A, Salvarani C. (1999) Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin. Exp. Rheumatol. 17:419-25.
40. Barnes DA et al. (1998) Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest. 101:2910-9.
41. Firestein GS. NF-kappaB: Holy Grail for rheumatoid arthritis? (2004) Arthritis Rheum. 50:2381-6.
42. Tedder TF, Steeber DA, Chen A, Engel P. (1995) The selectins: vascular adhesion molecules. FASEB. J. 9:866-73.
43. Hosaka S, Shah MR, Pope RM, Koch AE. (1996) Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. Clin. Immunol. Immunopathol. 78:276-82.
44. Bullard DC et al. (1999) Acceleration and increased severity of collagen-induced arthritis in P-selectin mutant mice. J. Immunol. 163:2844-9.
45. Utku N et al. (1998) Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 9:509-18.
46. Utku N, Boerner A, Tomschegg A, Bennai-Sanfourche F, Bulwin GC, Heinemann T, Loehler J, Blumberg RS, Volk HD. (2004) TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J. Immunol. 15:2342-52
47. Tomlinson MG, Heath VL, Turck CW, Watson SP, Weiss A. (2004) SHIP family inositol phosphatases interact with and negatively regulate the Tec tyrosine kinase. J. Biol. Chem. 279:55089-96.
48. Aguado B, Campbell RD. (1998) Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex. J. Biol. Chem. 273:4096-105.
49. West J et al. (1997) Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. DNA. Cell. Biol. 16:691-701.
50. Adachi H, Tsujimoto M. (2002) FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities. J. Biol. Chem. 277:34264-70.
51. Tamura Y et al. (2003) FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J. Biol. Chem. 278:12613-7.
52. Salmi M, Koskinen K, Henttinen T, Elima K, Jalkanen S. (2004) CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 104:3849-57.
53. Devauchelle V et al. (2004) DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes. Immun. 5:597-608.
54. Watanabe N et al. (2002) Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem. Biophys. Res. Commun. 294:1121-9.
55. van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL. (2003) Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes. Immun. 4:187-96.
56. Bovin LF et al. (2004) Blood cell gene expression profiling in rheumatoid arthritis: discriminative genes and effect of rheumatoid factor. Immunol. Lett. 93:217-26.
57. Olsen N et al. (2004) A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 63:1387-92.
58. Maas K et al. (2002) Cutting edge: molecular portrait of human autoimmune disease. J. Immunol. 169:5-9.
59. Hirano T. et al. (2000) Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis. Immunopharmacology 49:411-7.
60. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. (1996) Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). Clin. Exp. Immunol. 106:190-6.
61. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. (1997) Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum. 40:639-47.